Torsdag 18 December | 15:54:23 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-05 09:00 Kvartalsrapport 2026-Q3
2026-08-20 09:00 Kvartalsrapport 2026-Q2
2026-05-21 N/A Årsstämma
2026-05-07 09:00 Kvartalsrapport 2026-Q1
2026-03-31 08:00 Bokslutskommuniké 2025
2025-12-17 - Extra Bolagsstämma 2026
2025-11-25 - Split SUBGEN 1000:1
2025-11-05 - Extra Bolagsstämma 2025
2025-08-29 - Kvartalsrapport 2025-Q2
2025-07-01 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2025-06-30 - Årsstämma
2025-03-05 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-07-01 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2024-06-28 - Årsstämma
2024-04-26 - Extra Bolagsstämma 2024
2024-03-29 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-22 - Årsstämma
2023-06-01 - Kvartalsrapport 2023-Q1
2023-05-16 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2023-03-31 - Bokslutskommuniké 2022
2023-01-20 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-21 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2022-06-20 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-29 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2021-06-28 - Årsstämma
2021-05-25 - Kvartalsrapport 2021-Q1
2021-03-09 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Subgen AI utvecklar både infrastruktur och proprietär agentcentrerad AI-as-a-Service-programvara, med varumärket Serenity Star. Bolagets lösningar är utformade för att skala upp och accelerera implementeringen av AI i organisationer. Subgen AI levererar tjänster till kunder inom sektorer som hälso- och sjukvård, energi, juridik och personal. Subgen AI är verksamt i Europa, Latinamerika och USA.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2024-11-15 08:00:00

“We are expanding our product capabilities as well as advancing solutions that are directly aligned with our professional market focus in oral health.” Marco Witteveen, CEO of Magnasense AB

July – October 2024*

• Total income amounted to SEK 0M (0,2M)
• Loss before tax amounted to SEK -14,0M (-18,3M)
• Cash and cash equivalents at the end of the quarter was SEK 1,8M (23,4M)
• Earnings per share** SEK -0,32 (-0,61)
• Equity ratio*** at 30 September 2024 was -37 (12) %.

Significant events during the period

• Melissa Grant, Associate Professor at the University of Birmingham’s School of Dentistry, joined Magnasense’s Scientific Advisory Board.

• Aegirbio AB changed its name to Magnasense AB, to better reflect core assets and focus.

• Directed issues of 13,196,289 shares to Atlas Special Opportunities, including 12,249,215 shares following conversions of SEK 5,0M of loan notes, and a further issue of 947,074 transaction fee shares.

• Calls for payments of SEK 5,0M from Atlas Special Opportunities under Tranche 3 of the loan facility.

• Vicki Johnson joined Magnasense AB as Interim CFO, succeeding Christel Dahlberg.

• Payment period for business-critical supplier invoices totalling USD 970,000 extended (SEK 9,8M), with an agreement to issue 9.5 million warrants subject to approval at an EGM.

• A feasibility study to explore potential technology development opportunities with Salignostics Ltd was initiated.

• Filed a patent application for an advanced detection system designed to improve sensitivity and accuracy of magnetic test strips using superparamagnetic nanoparticles.

• Magnasense AB arranged short term loans totalling SEK 3,0M from board members.

Significant events after the period

• Directed issue to Atlas Special Opportunities of 13,090,908 shares being conversion of debt SEK 1,5M, and SEK 1,5M allotment of transaction fee shares.

* Compared to the same period in 2023
** Earnings per share: Profit for the period divided by the weighted average number of shares, which as of 2024-09-30 amounted to 35,388,621 shares before dilution. The corresponding number for the same period in the previous year was 24,575,099 shares.
** Equity ratio: Equity divided by total capital.